Get the Stockscreener App
1.77
6.63%
0.11
After Hours:
1.74
-0.03
-1.69%
Lineage Cell Therapeutics Inc stock is traded at $1.77, with a volume of 2.46M.
It is up +6.63% in the last 24 hours and up +32.09% over the past month.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
See More
Previous Close:
$1.66
Open:
$1.68
24h Volume:
2.46M
Relative Volume:
1.54
Market Cap:
$404.19M
Revenue:
$8.95M
Net Income/Loss:
$-21.49M
P/E Ratio:
-14.75
EPS:
-0.12
Net Cash Flow:
$-29.24M
1W Performance:
+3.51%
1M Performance:
+32.09%
6M Performance:
+276.76%
1Y Performance:
+106.92%
1-Day Range:
$1.645
$1.77
1-Week Range:
$1.63
$1.83
52-Week Range:
$0.3651
$1.83
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
Name
Lineage Cell Therapeutics Inc
Sector
Industry
Phone
510-871-4188
Address
2173 Salk Avenue, Suite 200, Carlsbad, CA
Compare LCTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.77 | 379.07M | 8.95M | -21.49M | -29.24M | -0.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-24 | Initiated | Craig Hallum | Buy |
| Nov-02-22 | Initiated | Robert W. Baird | Outperform |
| Jun-14-22 | Initiated | B. Riley Securities | Buy |
| Aug-19-21 | Initiated | Noble Capital Markets | Outperform |
| Mar-31-21 | Initiated | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc Stock (LCTX) Latest News
Will Lineage Cell Therapeutics Inc. stock outperform international peersTrade Exit Report & Consistent Profit Trading Strategies - newser.com
What the charts say about Lineage Cell Therapeutics Inc. todayJuly 2025 Intraday Action & Precise Entry and Exit Recommendations - newser.com
Analyzing drawdowns of Lineage Cell Therapeutics Inc. with statistical tools - newser.com
Why Lineage Cell Therapeutics Inc. stock remains undervaluedGap Down & Comprehensive Market Scan Insights - newser.com
How institutional ownership impacts Lineage Cell Therapeutics Inc. stockDay Trade & Breakout Confirmation Trade Signals - newser.com
Developing predictive dashboards with Lineage Cell Therapeutics Inc. data2025 Earnings Impact & Reliable Breakout Stock Forecasts - newser.com
Can Lineage Cell Therapeutics Inc. stock ride next bull market cycleWeekly Investment Report & Weekly Hot Stock Watchlists - newser.com
How Lineage Cell Therapeutics Inc. stock reacts to Fed tighteningJuly 2025 PreEarnings & Long Hold Capital Preservation Plans - newser.com
Applying sector rotation models to Lineage Cell Therapeutics Inc.Risk Management & Expert Approved Momentum Trade Ideas - newser.com
Can Lineage Cell Therapeutics Inc. stock withstand economic slowdownTrade Risk Assessment & Long-Term Safe Investment Ideas - newser.com
Lineage Cell Therapeutics Hits New 52-Week High of $1.82 - Markets Mojo
Can Lineage Cell Therapeutics Inc. stock maintain operating marginsPortfolio Return Summary & Risk Controlled Stock Pick Alerts - newser.com
Long term hold vs stop loss in Lineage Cell Therapeutics Inc.2025 Top Decliners & Smart Swing Trading Techniques - newser.com
Spinal Cord Injury Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen - Barchart.com
Stem Cell Therapy Market Forecast to 2033: Growth Driven - openPR.com
Key resistance and support levels for Lineage Cell Therapeutics Inc.2025 Growth vs Value & Low Risk Profit Maximizing Plans - newser.com
What technical models suggest about Lineage Cell Therapeutics Inc.’s comebackMarket Sentiment Report & Safe Swing Trade Setups - newser.com
Can Lineage Cell Therapeutics Inc. hit a new high this monthSell Signal & Verified Short-Term Trading Plans - newser.com
What analysts say about Lineage Cell Therapeutics Inc stockSector Rotation Strategies & Minimal Capital Growth Plans - earlytimes.in
Can momentum traders help lift Lineage Cell Therapeutics Inc.New Guidance & Community Trade Idea Sharing - newser.com
Price momentum metrics for Lineage Cell Therapeutics Inc. explained2025 Key Lessons & Weekly Top Gainers Trade List - newser.com
Is Lineage Cell Therapeutics Inc. stock cheap vs fundamentalsJuly 2025 WrapUp & Daily Profit Focused Stock Screening - newser.com
Using R and stats models for Lineage Cell Therapeutics Inc. forecastingJuly 2025 Price Swings & Community Trade Idea Sharing Platform - newser.com
Advanced analytics toolkit walkthrough for Lineage Cell Therapeutics Inc.2025 Risk Factors & AI Based Trade Execution Alerts - newser.com
Using data tools to time your Lineage Cell Therapeutics Inc. exitWeekly Trade Summary & Growth-Oriented Investment Plans - newser.com
Goldman Sachs Group Inc. Sells 34,963 Shares of Lineage Cell Therapeutics, Inc. $LCTX - Defense World
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Trading Up 4.7%Should You Buy? - MarketBeat
Lineage Cell Therapeutics Hits New 52-Week High of $1.72 - Markets Mojo
Lineage Cell Therapeutics Inc Stock (LCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):